{"id":"W4411638096","doi":"10.1016/j.euo.2025.04.025","title":"PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes","year":2025,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Manchester Biomedical Research Centre; Merck Sharp and Dohme; Institute of Cancer Research; Prostate Cancer UK; Cancer Research UK; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Movember Foundation","keywords":"Medicine; Pembrolizumab; Prostate cancer; Open label; Oncology; Internal medicine; Castration; Clinical trial; Immune system; Immunotherapy; Cancer; Immunology; Hormone","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002680762,0.001465718,0.001005522,0.0004593718,0.0002877355,0.0006221282,0.0008014185,0.00102706,0.00626777],"category_scores_gemma":[0.001646898,0.0004042635,0.0008388742,0.0002302197,0.0008355559,0.0007804876,0.0004864074,0.00186439,0.0007310076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007323076,"about_ca_system_score_gemma":0.001084243,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003143936,"about_ca_topic_score_gemma":0.0008822456,"domain_scores_codex":[0.9991166,0.0005708464,0.00002901511,0.0001279809,0.00007629098,0.00007919642],"domain_scores_gemma":[0.999318,0.000177335,0.0002010598,0.00005070163,0.00004183333,0.0002111283],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8654421,0.02638934,0.005584887,0.0009452829,0.0009318026,0.0003116092,0.0002764701,0.003061229,0.03480972,0.0006853156,0.00287674,0.05868556],"study_design_scores_gemma":[0.7866151,0.1967473,0.008148472,0.00003888783,0.000235044,0.0002643066,0.00003256841,0.001523022,0.003794199,0.0003249297,0.002252312,0.00002381402],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905397,0.001158862,0.0006401228,0.0005329282,0.00008044094,0.003506567,0.001217185,0.00009226664,0.00223201],"genre_scores_gemma":[0.9866769,0.0006829464,0.002931359,0.0005579157,0.0001253313,0.003444668,0.00169142,0.00003418557,0.003855252],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00626777,"threshold_uncertainty_score":0.02096772,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07294500427301906,"score_gpt":0.3603880609852758,"score_spread":0.2874430567122568,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}